News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Align reported record Clear Aligner shipments but cut fiscal 2026 revenue to $4.11–$4.13B.
  • Systems revenue weakness and a lower ASP outlook forced Align's guidance reduction.
  • Competition has eased, but ASP pressure keeps Align's growth outlook at risk.
  • Agios' mitapivat sales rose to $44.7M in Q2, supporting commercial momentum.
  • FDA review-window headlines pressured Agios' stock, creating a buy-the-dip opportunity.
  • Analysts upgraded Agios to a 180-day long trade tied to approval clarity.

Latest Articles

Planet Labs: The Q2 Proof Point That Needs to Arrive to Earn Its Multiple

Planet Labs: The Q2 Proof Point That Needs to Arrive to Earn Its Multiple

Planet Labs trades near $25 with a market cap of about $8.8B and a stretched price-to-sales multiple (~26x). The company has visible growth - recent revenue prints near $94M and a reported ~$900M backlog - but margins, free cash flow conversion, and dilution risk are the items investors need to see improve in the Q2 report to defend the current val…

Jakarta Stocks Rise as Infrastructure, Financials and Agriculture Lead Gains

Jakarta Stocks Rise as Infrastructure, Financials and Agriculture Lead Gains

Indonesia's benchmark IDX Composite climbed 1.59% at Monday's close in Jakarta, supported by advances in Infrastructure, Financials and Agriculture sectors. Notable top performers included Dana Brata Luhur PT (TEBE), Yanaprima Hastapersada Tbk (YPAS) and Asia Sejahtera Mina Tbk (AGAR), while Bersama Mencapai Puncak PT Tbk (BAIK), Multitrend Indo Tb…

Correction: Director/PDMR Shareholding

Correction: Director/PDMR Shareholding

The Magnum Ice Cream Company N.V. has amended a prior announcement to correct share prices related to the vesting of share awards for several of its senior executives. The transactions involve ordinary shares traded on both the Amsterdam and London Stock Exchanges, with vesting prices and volumes disclosed. The correction aligns with regulations un…

Kepler Lowers Mowi Rating as Feed and Fishmeal Inflation Looms

Kepler Lowers Mowi Rating as Feed and Fishmeal Inflation Looms

Kepler Cheuvreux downgraded Mowi ASA from Buy to Hold and reduced its price target from 225 to 200 Norwegian crowns, pointing to escalating raw material cost pressures that could erode earnings despite stronger-than-expected second-quarter results. The broker highlighted a healthy Q2 operating EBIT and volume growth but warned of rising feed-relate…

AmpliTech: Reset Expectations, Compelling Risk-Adjusted Entry Near $4

AmpliTech: Reset Expectations, Compelling Risk-Adjusted Entry Near $4

AmpliTech (AMPG) has legitimately advanced its Open RAN radios and won technical validations, but recent financing and mixed cash flow argue for tempered revenue expectations. At roughly $4.06 today the shares offer a better risk/reward than during the June rally. This is a tactical mid-term long idea that leans on improving order flow, an authoriz…

Chord Energy: Cash Flow Strength Makes Buybacks a Credible Growth Engine

Chord Energy: Cash Flow Strength Makes Buybacks a Credible Growth Engine

Chord Energy's balance sheet and free cash flow profile make a buyback-and-FCF-per-share thesis viable. With free cash flow near $1.19B, modest leverage, and a sub-9x P/E, the stock trades at a valuation that gives management room to repurchase shares while still funding dividends and selective reinvestment. I recommend a position-sized long with a…

Genco Shipping & Trading Limited Issues Open Letter to Shareholders Following Withdrawal by Diana Shipping Inc. of its Offer

Genco Shipping & Trading Limited Issues Open Letter to Shareholders Following Withdrawal by Diana Shipping Inc. of its Offer

Genco Shipping & Trading Limited issued an open letter to shareholders following Diana Shipping Inc.'s withdrawal of its offer to acquire Genco. The Genco board emphasized that Diana's offer undervalued Genco's net asset value, involved misleading tactics, and failed to respect existing shareholder dividends. Genco reaffirmed its comprehensive valu…

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

argenx announced that its Phase 3 ALKIVIA study of VYVGART Hytrulo (efgartigimod) in autoimmune myositis met its primary endpoint, showing significant and sustained improvement in total disease activity score at 52 weeks in the combined population of IMNM and DM patients. This is the first Phase 3 trial demonstrating meaningful clinical benefit in …

Nasdaq and Moomoo host inaugural Investor Day

Nasdaq and Moomoo host inaugural Investor Day

Nasdaq and Moomoo Australia and New Zealand, operating the moomoo trading platform and owned by Futu Holdings Ltd, jointly hosted their first Investor Day in Sydney. The event included expert panels and a keynote by Nasdaq's chief economist discussing macroeconomic forces and the AI trade outlook, aiming to provide Australian retail investors with …

Oil steadies as Hormuz shipping slows and U.S.-Iran talks remain stalled

Oil steadies as Hormuz shipping slows and U.S.-Iran talks remain stalled

Oil prices showed little movement in early trade as vessel traffic through the Strait of Hormuz slowed over the weekend and no agreement materialized to end the U.S.-Iran conflict. Brent ticked up modestly while U.S. crude slipped slightly, leaving markets to weigh supply disruption risks against informal routing and other stopgaps.

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back Pain

Mesoblast Limited has completed patient treatment in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease. The trial treated 350 patients—exceeding the initial target—evaluating pain reduction and improvements in function and quality of life. The therapy has received RMAT designation from…